Ítem
Acceso Abierto

Mechanism of action of Type 2 Sodium-Glucose Cotransporter Inhibitors: Beyond glycaemic control

Mostrar el registro sencillo de la publicación
dc.creatorSandoval, Andrés Felipe Buitragospa
dc.creatorVallejo, Carlos Andrés Sánchezspa
dc.date.accessioned2020-05-25T23:59:13Z
dc.date.available2020-05-25T23:59:13Z
dc.date.created2020spa
dc.description.abstractType 2 Sodium-Glucose Cotransporter (SGLT2) Inhibitors exercise their glucose-lowering effect through the inhibition of glucose reabsorption in the kidney. However, the cardiovascular and renal effects, as well as in those of cardiac failure, seem to occur independently from the glucose–lowering effects of these drugs. The principal mechanisms of action that explain their cardiovascular benefits are the hypotensive effect and the decrease in fill pressures, as well as direct effects on the metabolism of the myocardial cell. There is also a reduction in the urine albumin, as well as non-glycaemic effects, and a decrease in adipose tissue, with an increase in haematocrit and urine uric acid. Each one of these novel mechanisms is described in this article. © 2019eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.rccar.2019.12.003
dc.identifier.issn1205633
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23005
dc.language.isoengspa
dc.publisherElsevier B.V.spa
dc.relation.citationEndPage25
dc.relation.citationStartPage22
dc.relation.citationTitleRevista Colombiana de Cardiologia
dc.relation.citationVolumeVol. 27
dc.relation.ispartofRevista Colombiana de Cardiologia, ISSN:1205633, Vol.27,(2020); pp. 22-25spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85079117151&doi=10.1016%2fj.rccar.2019.12.003&partnerID=40&md5=02afc6933df4d1c15129cb728bd95865spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAlbuminspa
dc.subject.keywordSodium glucose cotransporter inhibitorspa
dc.subject.keywordUric acidspa
dc.subject.keywordAdipose tissuespa
dc.subject.keywordAntidiarrheal activityspa
dc.subject.keywordAntihypertensive activityspa
dc.subject.keywordArticlespa
dc.subject.keywordCardiac muscle cellspa
dc.subject.keywordCell metabolismspa
dc.subject.keywordDrug mechanismspa
dc.subject.keywordHumanspa
dc.subject.keywordUric acid urine levelspa
dc.subject.keywordDiabetesspa
dc.subject.keywordHeart failurespa
dc.subject.keywordTreatmentspa
dc.titleMechanism of action of Type 2 Sodium-Glucose Cotransporter Inhibitors: Beyond glycaemic controlspa
dc.title.TranslatedTitleMecanismos de acción de los inhibidores de cotransportador de sodio y glucosa tipo 2 —SGLT2—: Más allá del control de la glicemiaspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
1-s2-0-S0120563319302220.pdf
Tamaño:
476.49 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos